The Great Repricing: Maximizing Enterprise Value Across the Product Life Cycle

In the first four articles of “The Great Repricing” series, we've established that the U.S. pharmaceutical market has fragmented into three distinct payer economies — commercial, government and cash. Each operates under different economic incentives, regulatory constraints, pricing logic and distribution models. Those markets are no longer evolving independently. They interact continuously, and manufacturers must now commercialize products across all three simultaneously.

That raises a much bigger question: How should pharmaceutical manufacturers maximize the enterprise value of a product over its entire life cycle? Historically, the answer was straightforward: develop the product, launch through commercial insurance, negotiate formulary access, accept whatever government business comes along through policy, support patients with affordability programs, defend the brand through patent expiry, and eventually manage the decline after loss of exclusivity or simply put it on life support as a cash cow. That commercialization model was built for a market dominated by commercial insurance. It is no longer sufficient.

The next generation of commercialization strategy must recognize that products migrate across payer economies throughout their lives. The objective is no longer simply maximizing access; it is maximizing enterprise value.

Government Defines the Playing Field

Given the size, scope and impact on net revenues, every commercialization strategy should begin by financially modeling government as a payer. It is the known. The constant. That statement would have sounded unusual 20 years ago. Today, it reflects reality. Government pricing is largely statutory. Manufacturers negotiate very little. Instead, they operate within rules established through the average manufacturer price, average sales price, Medicaid best price, the Inflation Reduction Act, the 340B Drug Pricing Program, Federal Supply Schedule pricing, Medicare Parts B and D, and an expanding set of international reference pricing initiatives. Those rules increasingly establish the boundaries within which commercial strategies can operate.

Commercial is no longer independent of government. Anyone who's accidentally given an entity, such as a staff model health maintenance organization, a record-setting deep price without fully vetting the downstream government — and therefore net revenue — impacts knows exactly what I'm referring to.

Managed Medicaid continues to grow. Medicare Part D, which has existed for only the past 20 years, has become one of the largest pharmaceutical benefit platforms in the country. Best price, inflation rebates and 340B exposure all influence commercial pricing decisions.

Government is no longer simply another payer; it is the foundation upon which every commercialization strategy must be built.

Commercial Is No Longer the Default Answer

For the past 40 years, the pharmaceutical industry has largely assumed that every successful product should be commercialized through commercial insurance. That assumption deserves to be challenged.

With more than 1,400 products subject to formulary blocks, egregious prior authorizations, step edits, underreimbursed pharmacies, rising copays, copay accumulator programs and increasing deductibles, plan sponsors and patients are actively exploring an array of alternatives. That said, commercial insurance continues to be the optimal strategy for many product archetypes. Oncology, rare disease, cell and gene therapy, and other products serving significant unmet medical need will continue to depend on commercial and government reimbursement.

But other products operate under very different economics. General medicine brands entering mature therapeutic classes face increasing rebate demands, aggressive utilization management, formulary exclusions and growing generic competition. Some specialty categories are beginning to experience similar dynamics as biosimilars proliferate. The question should no longer be: How do we obtain coverage? Instead, it should be: Does commercial coverage maximize enterprise value in sync with our payer and channel forecasts?

For some products, the answer remains yes. Increasingly, for others, the answer may be no.

Cash Is a Commercialization Strategy

One of the industry's biggest misconceptions is viewing cash as an affordability tactic rather than a commercialization strategy. Cash should not be viewed as a last resort for uninsured patients; it should be evaluated as a deliberate channel. There are at least two points in a product's life cycle where cash deserves serious consideration.

The first — and perhaps most obvious — is later in the product life cycle. As therapeutic classes mature, rebate demands increase, utilization management becomes more aggressive, and generics or biosimilars enter the market, insurance can begin suppressing demand for the brand rather than creating it. At that point, cash becomes an alternative commercialization model — not necessarily because insurance disappeared, but because the economics changed.

The second, and newer, point is at launch. Novo Nordisk and Eli Lilly and Company experienced this with the lack of coverage for their weight-loss products. When manufacturers anticipate delayed, restricted or unlikely formulary access, cash may create faster patient access than waiting for insurance coverage. Rather than giving product away through samples, quick-start or bridge programs while negotiating rebates, manufacturers can establish transparent pricing that reinforces product value and begins building demand immediately.

The commercialization strategy changed because the product life cycle changed. Manufacturers are not organized for this yet.

Commercialization Should Follow Product Archetypes

One of the recurring themes throughout this series has been that not all products are created equal — and neither should their commercialization strategies be.

Manufacturers have become accustomed to applying one commercial model across an entire portfolio. I remember in the 1990s there were nine playbooks we all used to launch products. Those days were so simple.

The future requires segmentation. Products with significant unmet medical need may remain heavily dependent on insurance-backed reimbursement throughout their lives. General medicine brands may transition from commercial toward cash as competition intensifies. Specialty products may split, with preferred products remaining within insurance while nonpreferred biosimilars increasingly compete through cash channels.

Loss of exclusivity should no longer represent the end of commercialization planning but the beginning of a different commercialization strategy. The objective is no longer maximizing one channel; it is maximizing the lifetime enterprise value of the asset.

We Forecast Revenue. We Should Forecast Commercialization.

One of the biggest gaps I see in commercialization planning is how manufacturers forecast the future. The accuracy of a weekly changing forecast has become a punchline among commercial planning experts, but management teams don't fully realize how dangerous that is.

Most launch plans I see before we get there extend 12 to 24 months post launch. Some have a long-range plan that extends to year 3. No one believes the forecast beyond year 3.

Forecasts typically focus on prescription volume, gross sales, net sales and gross-to-net performance. Those remain important, but they represent only part of the picture. Increasingly, manufacturers should be building multigenerational commercialization forecasts by both payer economy and physical channel. Not simply: How much revenue will this product generate? But: Where will that revenue come from? How will commercial, government and cash evolve over time? What happens after patent expiry? What commercialization strategy maximizes recoverable enterprise value across the product's entire economic life?

At IntegriChain, we have begun building commercialization plans that extend from launch through five years post patent expiry. A great example of why is iPay. If your brand is too successful too fast, it could wind up as a losing proposition.

We increasingly evaluate products across their full life cycle, recognizing that commercialization strategy should evolve just as the competitive landscape evolves. Anyone who's launched or defended products in immunology over the past five years knows this all too well.

A product does not stop creating value because it loses exclusivity; it simply requires a different commercialization strategy.

The Organization Is Built for Yesterday

This shift exposes an organizational challenge. Pharmaceutical companies remain structured around a commercial insurance model developed over the past four decades. Market access negotiates coverage. Government pricing manages compliance. Trade manages distribution. Patient services navigates insurance. Finance forecasts gross-to-net. Each function performs well within its own discipline.

But few organizations are designed to answer a much larger question: What is the optimal commercialization model for this product over its entire life cycle? Even fewer organizations have clear ownership of cash as a commercial channel.

The result is predictable. Companies optimize individual functions while missing opportunities to optimize enterprise value across the portfolio. Cash is not struggling because the model doesn't work. Manufacturers are struggling because their organizations were never built to commercialize products across three-payer economies simultaneously.

The Next Generation of Commercialization

The pharmaceutical industry spent 40 years optimizing for a market dominated by commercial insurance. The next 40 years will require something fundamentally different. Plan sponsors and patients are demanding it.

Manufacturers will need to think beyond coverage and beyond gross-to-net performance. They will need to evaluate products by archetype, forecast commercialization across the entire product life cycle, and determine which payer economy creates the greatest enterprise value at each stage of that journey.

Commercialization will become more dynamic. Organizations will become more integrated. Pricing, payer economy strategy, policy, provider strategy, channel strategy and patient access will become increasingly inseparable.

The companies that adapt first will not simply commercialize products more efficiently. They will recover more value from every asset they bring to market.

Looking Ahead

In the final installment of “The Great Repricing,” we'll look beyond today's market and explore the commercialization organization of the future and how it will impact pipeline assets. We'll discuss how AI, digital health, direct-to-patient models, pharmacy evolution, organizational design and new channel architectures will reshape pharmaceutical commercialization over the next decade.

The central theme of this series is that the U.S. pharmaceutical market is no longer governed by a single pricing system. Instead, three payer economies — commercial, government and cash — are emerging with different incentives, regulatory structures and access pathways. The manufacturers that succeed in the coming decade will be those that learn to navigate all three simultaneously.

Bill Roth is the senior vice president of consulting and advisory services at IntegriChain.